This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
TAK vs. STVN: Which Stock Is the Better Value Option?
by Zacks Equity Research
TAK vs. STVN: Which Stock Is the Better Value Option?
SDZNY vs. STVN: Which Stock Is the Better Value Option?
by Zacks Equity Research
SDZNY vs. STVN: Which Stock Is the Better Value Option?
Implied Volatility Surging for Stevanato Group (STVN) Stock Options
by Zacks Equity Research
Investors need to pay close attention to Stevanato Group (STVN) stock based on the movements in the options market lately.
Stevanato Group (STVN) Q2 Earnings Match Estimates
by Zacks Equity Research
Stevanato (STVN) delivered earnings and revenue surprises of 0% and 1.43%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Jazz Pharmaceuticals (JAZZ) Reports Next Week: Wall Street Expects Earnings Growth
by Zacks Equity Research
Jazz (JAZZ) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Analysts Estimate Stevanato Group (STVN) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Stevanato (STVN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
USNA vs. STVN: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
USNA vs. STVN: Which Stock Is the Better Value Option?
USNA or STVN: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
USNA vs. STVN: Which Stock Is the Better Value Option?
Fusion Pharmaceuticals Inc. (FUSN) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
by Zacks Equity Research
Fusion Pharmaceuticals (FUSN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Stevanato Group (STVN) to Report Q1 Results: What You Should Expect
by Zacks Equity Research
Stevanato (STVN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
TAK or STVN: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
TAK vs. STVN: Which Stock Is the Better Value Option?
Stevanato Group (STVN) Q3 Earnings Meet Estimates
by Zacks Equity Research
Stevanato (STVN) delivered earnings and revenue surprises of 0% and 3.22%, respectively, for the quarter ended September 2023. Do the numbers hold clues to what lies ahead for the stock?
TAK vs. STVN: Which Stock Is the Better Value Option?
by Zacks Equity Research
TAK vs. STVN: Which Stock Is the Better Value Option?
Akebia Therapeutics (AKBA) May Report Negative Earnings: Know the Trend Ahead of Q3 Release
by Zacks Equity Research
Akebia Therapeutics (AKBA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Stevanato Group (STVN) Reports Next Week: Wall Street Expects Earnings Growth
by Zacks Equity Research
Stevanato (STVN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
USNA or STVN: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
USNA vs. STVN: Which Stock Is the Better Value Option?
GRFS or STVN: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
GRFS vs. STVN: Which Stock Is the Better Value Option?
All You Need to Know About Stevanato (STVN) Rating Upgrade to Buy
by Zacks Equity Research
Stevanato (STVN) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Stevanato Group (STVN) Beats Q2 Earnings and Revenue Estimates
by Zacks Equity Research
Stevanato (STVN) delivered earnings and revenue surprises of 7.14% and 0.92%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
Strength Seen in Stevanato (STVN): Can Its 5.0% Jump Turn into More Strength?
by Zacks Equity Research
Stevanato (STVN) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Stevanato Group (STVN) Q1 Earnings Lag Estimates
by Zacks Equity Research
Stevanato (STVN) delivered earnings and revenue surprises of -7.69% and 1.80%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Will Akebia Therapeutics (AKBA) Report Negative Q1 Earnings? What You Should Know
by Zacks Equity Research
Akebia Therapeutics (AKBA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Stevanato Group (STVN) Earnings Expected to Grow: Should You Buy?
by Zacks Equity Research
Stevanato (STVN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Stevanato Group S.p.A. (STVN) Hit a 52 Week High, Can the Run Continue?
by Zacks Equity Research
Stevanato (STVN) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Here's Why You Should Hold Teladoc Health (TDOC) Stock Now
by Zacks Equity Research
Teladoc Health (TDOC) remains well-poised for growth on the back of solid revenues, sustained demand for virtual care services and sufficient cash-generating abilities.